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Introduction {#jdi12462-sec-0005}
============

Type 1 diabetes is an autoimmune disease characterized by immune‐mediated destruction of pancreatic β‐cells, resulting in permanent β‐cell loss and insulin deficiency. It is widely recognized that the major component of human leukocyte antigen (*HLA*) susceptibility to type 1 diabetes involves the *DRB1, DQA1* and *DQB1* genes[1](#jdi12462-bib-0001){ref-type="ref"}. Recent studies have suggested that genes in the HLA region other than DR and DQ also contribute to type 1 diabetes susceptibility[2](#jdi12462-bib-0002){ref-type="ref"}, [3](#jdi12462-bib-0003){ref-type="ref"}, [4](#jdi12462-bib-0004){ref-type="ref"}.

The association of *HLA* class I polymorphisms with the age at onset of type 1 diabetes in Caucasian populations has been previously reported[2](#jdi12462-bib-0002){ref-type="ref"}, [3](#jdi12462-bib-0003){ref-type="ref"}. *HLA* class I molecules, given their role in target‐cell recognition by CD8^+^ cytotoxic T lymphocytes, play a role in the ongoing immune response and, therefore, could affect the rate of pancreatic β‐cell destruction. This hypothesis might help explain the observed associations of *HLA* class I with type 1 diabetes, particularly the association of *HLA* class I with lymphocyte subpopulation. In addition, it has recently been observed that innate immune cell cross‐talk also occurs in the pancreas of young NOD mice and leads to the initiation of type 1 diabetes, with the interaction of immunoglobulin G (IgG)‐producing B‐1a cells, neutrophils and interferon‐α‐producing pDCs[5](#jdi12462-bib-0005){ref-type="ref"}.

With the requirement of secondary type 1 diabetes prevention trials and the selection of participants with impending diabetes, and the fact that thus far, scarce research is available regarding the association of T lymphocyte subpopulations and innate immunity with high‐risk *HLA* class I genes in patients with type 1 diabetes at the disease onset, we investigated whether typing for *HLA‐A*,*HLA‐B* and *HLA‐C* might complement screening for *HLA‐DRB1, DQB1* and *DQA1* in Chinese patients in Eastern China, and sought to characterize the clinical and immunological features of *HLA*‐typed youth with new‐onset type 1 diabetes.

Materials and Methods {#jdi12462-sec-0006}
=====================

Study Cohort {#jdi12462-sec-0007}
------------

A total of 212 patients with new‐onset type 1 diabetes included in this dataset were identified and examined at the Department of Endocrine and Metabolic diseases, Ruijin Hospital Affiliated to Shanghai Jiao‐Tong University School of Medicine, Shanghai, China, from April 2006 to October 2012. The average age at diagnosis was 20.2 ± 5.5 years, and the average duration of diabetes was 10 ± 6.4 weeks with 87 men and 125 women. A total of 200 healthy volunteers were included as controls, including 117 men and 83 women, with an average age of 23.6 ± 4.2 years, and had no family history of diabetes or overt autoimmune diseases and any chronic diseases. All the cases and controls were Han Chinese and from the East Chinese population belonging to the East Chinese states of Shanghai, Jiangsu and Zhejiang. Individuals with type 1 diabetes or not were diagnosed according to the diagnosis criteria of the World Health Organization and American Diabetes Association[6](#jdi12462-bib-0006){ref-type="ref"}. All cases are typical acute‐onset, ketosis prone, positive for glutamic acid decarboxylase antibodies. All the patients and 10 of the healthy volunteers were followed up for age at onset, relative with type 1 diabetes (yes vs no), diabetic ketoacidosis history (yes vs no), glucose level, glycated hemoglobin, fasting C‐peptide, peak value of C‐peptide during a 75‐g oral glucose tolerance test and area under C‐peptide release curve during an oral glucose tolerance test. To find the relationship between immunophenotypic changes and high‐risk haplotypes, the total percentages of neutrophils, natural killer (NK), T and B cells were examined, as well as the coexpression of surface molecules on lymphocytes associated with helper/cytotoxic capacity, activation status and other functions. In addition, the levels of several serum proteins, including glutamic acid decarboxylase antibodies, high‐sensitivity C‐reactive protein (hs‐CRP), IgG and interferon‐γ (IFN‐γ) were evaluated. All samples were collected with appropriate informed consent, and the protocol was approved by the local ethics committee and carried out in agreement with the Declaration of Helsinki as revised in 2000.

Genotyping Methods {#jdi12462-sec-0008}
------------------

*HLA* genotyping detection was carried out on 212 patients with type 1 diabetes and 200 healthy controls, with six loci, including *A*,*B*,*C*,*DRB1*,*DQB1* and *DQA1*, with a polymerase chain reaction sequence‐based typing system (Shanghai Tissuebank Biotechnology Co., Ltd., Shanghai, China). Genomic deoxyribonucleic acid was isolated from whole blood using the QiaAMP^®^ DNA mini kits (Qiagen GmbH, Hilden, Germany), and used to amplify *HLA* class I and class II genes by polymerase chain reaction with primers listed in Table S1. Amplicons were purified using ExoSAP protocols (Exonuclease I and Alkaline Phosphatase kits; Takara, Dalian, China) and sequenced using the ABI Prism BigDye Teminator Cycle Sequencing Reaction Ready kits (Applied Biosystems, Foster City, CA, USA) with the specific sequencing primers (Table S2). Sequences were analyzed using the ABI 3730xl genetic analyzer (Applied Biosystems). The sequences were then genotyped using uTYPE3.0 software and database 3.7 (Thermo Fisher Scientific Inc., Waltham, MA, USA). Class I *HLA* alleles were sequenced for exons 2, 3 and 4 in both directions, and class II *HLA* alleles were sequenced for exon 2 and 3 in both directions. To determine the ambiguity, allele‐specific sequencing was carried out using a set of group‐specific primers (HLA‐SBT kit; CATB, Shanghai, China). The deoxyribonucleic acid database of the same sequences of all known alleles were thereby compared to obtain accurate allele coding.

Flow Cytometry {#jdi12462-sec-0009}
--------------

Blood collection was carried out in 212 patients with type 1 diabetes and 10 healthy controls. The measurements of forward and side scatter were combined with CD45 to identify lymphocytes and exclude monocytes. The absolute subpopulations of lymphocyte numbers were calculated based on the total lymphocyte counts and the percentage of subpopulations of lymphocyte cells, as identified by flow cytometry using the EPICS XL (Beckman Coulter, Brea, CA, USA) and Divasoftware (BD Biosciences, Franklin Lakes, NJ, USA). The fraction of lymphocyte cell subsets was determined by multiple‐colors fluorescence activated cell sorter analysis using appropriate surface markers: anti‐CD3‐FITC (Clone UCHT1), anti‐CD4‐PE‐Cy7 (Clone 13B8.2), anti‐CD8‐APC‐H7 (Clone B9.11), anti‐CD45‐PerCP‐Cy5.5 (Clone J.33), anti‐CD45RA‐FITC (Clone ALB11), anti‐C62L‐PE (Clone DREG56), anti‐CD19‐APC (Clone J3.119) anti‐CD16‐PE (Clone 3GB), anti‐CD56‐PE (Clone N901), anti‐TCR PAN α/β‐FITC (TCR 1, Clone IP26A) and anti‐TCR PAN γδ‐PE (TCR 2, Clone IMMU510; Beckman Coulter).

Laboratory Assessment of Diabetes Status {#jdi12462-sec-0010}
----------------------------------------

The serum C‐peptide levels were measured by a radioimmunoassay using a commercially available kit (Roche Diagnostics, Penzberg, Germany). The lower limit of detection was 0.1 ng/mL, and undetected values were reported as 0.1 ng/mL. The serum levels of anti‐glutamic acid decarboxylase antibodies were also measured by a radioimmunoassay using a commercial kit (RSR Limited, Cardiff, UK), and the results were considered positive if the values were \>7.5 units/mL. Glycated hemoglobin was measured by high‐pressure liquid chromatography. The serum levels of hs‐CRP were measured using the latex enhanced immunoturbidimetric method. Both IgG and IFN‐γ were measured by enzyme‐linked immunosorbent assay (Gentaur, Kampenhout, Belgium) and flow cytometry (Beckman, High Wycombe, UK), respectively.

Statistical Analysis {#jdi12462-sec-0011}
--------------------

The Hardy--Weinberg test of *HLA* alleles and their linkage disequilibrium test results were analyzed using Arlequin 3.11 software (Institute of Ecology and Evolution, University of Bern, Bern, Switzerland). Statistical analysis was carried out with SPSS 17.0 (SPSS, Armonk, NY, USA). The results are shown as the mean ± standard deviation or as median (range), or otherwise documented as positive cases, constituent ratio or ratio. The difference between classified variables was tested using the χ^2^‐test or Fisher\'s exact test if the expected number of participants in any cell was less than five. [anova]{.smallcaps} analyses were carried out among the groups with a model that included the baseline values of the age of onset and duration of diabetes as covariates. C‐peptide, anti‐glutamic acid decarboxylase antibodies and hs‐CRP were studied on the logarithmic scale. All hypothesis testing was two‐tailed. We made the Bonferroni correction for the *P*‐values by the number of alleles with substantial frequencies (≥5%) in six loci including *HLA‐A*,*B*,*C*,*DRB1*,*DQB1* and *DQA1* respectively[7](#jdi12462-bib-0007){ref-type="ref"}. Statistical significance was defined as *P* \< 0.05.

Results {#jdi12462-sec-0012}
=======

*HLA* Alleles and Haplotypes {#jdi12462-sec-0013}
----------------------------

The association of *HLA* alleles and haplotypes with type 1 diabetes is shown in Tables [1](#jdi12462-tbl-0001){ref-type="table-wrap"}, S3 and S4. The frequencies of *A\*24:02*,*B\*58:01*,*C\*03:02* and *A\*33:03‐B\*58:01‐C\*03:02*,*DRB1\*03:01‐DQA1\*05:01‐DQB1\*02:01(DR3)* [1](#jdi12462-bib-0001){ref-type="ref"}, *DRB1\*04:XX‐DQA1\*03:01‐DQB1\*03:02(04XX: 04:01,04:04,04:05) (DR4)* [1](#jdi12462-bib-0001){ref-type="ref"} and *DRB1\*09:01‐DQA1\*03:02‐DQB1\*03:03(DR9)* [8](#jdi12462-bib-0008){ref-type="ref"} haplotypes were significantly higher in the patients with type 1 diabetes than the healthy controls (all *P* \< 0.05).

###### 

Comparison of human leukocyte antigen gene frequencies between type 1 diabetic patients and healthy controls

  Gene                           Type 1 diabetic patients (*n* = 212)   Healthy controls (*n* = 200)   *P*            Pc              OR       OR (95% CI)
  ------------------------------ -------------------------------------- ------------------------------ -------------- --------------- -------- ---------------
  Alleles                                                                                                                                      
  *HLA‐A*                                                                                                                                      
  *A\*24:02*                     85 (40.1)                              44 (22.0)                      7.6 × 10^−5^   6.86 × 10^−4^   2.373    1.539--3.658
  *A\*33:03*                     55 (25.9)                              36 (18.0)                      0.052          0.468           1.596    0.994--2.563
  *HLA‐B*                                                                                                                                      
  *B\*58:01*                     62 (29.2)                              21 (10.5)                      2.1 × 10^−6^   2.7 × 10^−5^    3.523    2.052--6.048
  *HLA‐C*                                                                                                                                      
  *C\*03:02*                     60 (28.3)                              21 (10.5)                      5.5 × 10^−6^   5.0 × 10^−5^    3.365    1.957--5.785
  Haplotypes                                                                                                                                   
  A‐B‐C                                                                                                                                        
  *A\*33:03‐B\*58:01‐C\*03:02*   46 (21.7)                              16 (8.0)                       1.0 × 10^−4^   --              3.187    1.738--5.843
  DRB1‐DQB1‐DQA1                                                                                                                               
  *DR3*                          81 (38.2)                              26 (13.0)                      5.5 × 10^−9^   --              4.138    2.518--6.799
  *DR4*                          31 (17.1)                              3 (1.5)                        3.2 × 10^−6^   --              11.247   3.380--37.420
  *DR9*                          87 (41.0)                              42 (21.0)                      1.2 × 10^−5^   --              2.618    1.692--4.052

Data are expressed as *n* (%). χ^2^ or Fisher\'s exact test. *DR3* = *DRB1\*03:01‐DQA1\*05:01‐DQB1\*02:01*,*DR4 = DRB1\*04:XX‐DQA1\*03:01‐DQB1\*03:02(04:XX: 04:01*,*04:04*,*04:05)*,*DR9 = DRB1\*09:01‐DQA1\*03:02‐DQB1\*03:03*. --, Not available; CI, confidence interval; HLA, human leukocyte antigen; OR, odds ratio; Pc, corrected *P*‐values.

John Wiley & Sons, Ltd

The differences in allele frequencies between controls and cases for these alleles could be exclusively due to the strong linkage disequilibrium between the *HLA* class I and class II loci. To address this issue, we computed the normalized linkage disequilibrium in the type 1 diabetic patients (Table [2](#jdi12462-tbl-0002){ref-type="table-wrap"}). The strongest linkage disequilibrium observed in both samples was between the well‐known high‐risk haplotypes, *DRB1\*03:01‐DQB1\*02:01* and *DRB1\*09:01‐DQB1\*03:03*, respectively. The other apparently predisposing allele, *A\*24:02*, showed no significant linkage disequilibrium to any particular *DR‐DQ* haplotype. Of the apparently predisposing alleles, *A\*33:03* showed a very strong linkage disequilibrium with *B\*58:01*, which explains why *A\*33:03* often appeared with *B\*58:01* among patients, whereas both these two alleles showed no significant linkage disequilibrium with the high‐risk haplotypes *DR3, DR4* and *DR9* (Tables S5--10). Accordingly, primary association data for *HLA* region markers remained significantly associated with type 1 diabetes after computation of linkage disequilibrium.

###### 

Normalized linkage disequilibrium between human leukocyte antigen class I and human leukocyte antigen class II alleles (*n =* 212)

  Haplotype   D'        *r* ^2^   χ^2^   *P*‐value   
  ----------- --------- --------- ------ ----------- ---------
  *HLA‐A*     *HLA‐B*                                
  *33:03*     *58:01*   0.76      0.47   171.06      \<0.001
  *DRB1*      *DQB1*                                 
  *03:01*     *02:01*   0.90      0.80   288.70      \<0.001
  *09:01*     *03:03*   0.72      0.52   188.98      \<0.001
  *HLA‐B*     *DQA1*                                 
  *58:01*     *05:01*   0.80      0.39   140.84      \<0.001

Only haplotypes that showed significant linkage disequilibrium are listed. HLA, human leukocyte antigen.

John Wiley & Sons, Ltd

We then assessed the risk of both the *A33* haplotype and *A\*24:02* allele with these stratified *HLA‐DR‐DQ* haplotypes compared with the results presented earlier, which were not stratified by *HLA*‐*DR‐DQ* haplotype. Haplotype *A33* was associated with case chromosomes on *DR3* (*P* = 4.0 × 10^−6^, odds ratio 5.09) and is also associated with *DR9* haplotypes (*P* = 0.004, odds ratio 13.00; Table [3](#jdi12462-tbl-0003){ref-type="table-wrap"}), with the exception of *DR4*, where there was no increased risk associated with the *A33* haplotype (*P* = 0.499).

###### 

Analysis of case and control chromosomes for the risk associated with the haplotype *A\*33:03‐B\*58:01‐C\*03:02*, stratified by *HLA‐DR‐DQ* haplotype

  Haplotype   Type 1 diabetes patients (*n* = 212)   Healthy control (*n* = 200)   OR (95% CI)   *P*                          
  ----------- -------------------------------------- ----------------------------- ------------- ----- ---------------------- --------------
  *DR3*       41                                     19.3                          9             4.5   5.09 (2.40--10.78)     4.0 × 10^−6^
  *DR4*       2                                      0.9                           0             0.0   NA                     0.499
  *DR9*       13                                     6.1                           1             0.5   13.00 (1.69--100.32)   0.004

*A33 = A\*33:03‐B\*58:01‐C\*03:02*. χ^2^ or Fisher\'s exact test. CI, confidence interval; NA, not available; OR, odds ratio.

John Wiley & Sons, Ltd

Clinical Characteristics in Patients with High‐risk *A33*‐*DR3* and *A33‐DR9* Haplotypes {#jdi12462-sec-0014}
----------------------------------------------------------------------------------------

To explore whether there were cooperative effects between the *A33* and high‐risk *DR3* or *DR9* haplotypes, we assessed the correlation between clinical characteristics and *A33* haplotype on *DR3* or *DR9*. The participants were divided into two groups according to different high‐risk haplotypes. Haplotypes *A33‐DR3* and *A33‐DR9* were detected in 41 and 13 out of 212 patients with type 1 diabetes, respectively (19.3% and 6.1%). There were 126 and 92 participants in the *A33‐DR3*‐negative and *A33‐DR9*‐negative subgroups, respectively (59.4% and 43.4%). *A33‐DR3*‐positive carriers were referred to as patients with both haplotype *A33* and haplotype *DR3*, whereas *A33‐DR3*‐negative carriers were identified as participants without either haplotype *A33* or haplotype *DR3*. The identification of *A33‐DR9*‐positive and *A33‐DR9*‐negative subgroups was the same as that of the *A33‐DR3* subgroups. Clinical features, such as the age at onset, duration of diabetes, frequency of presence with diabetic ketoacidosis history and relative with type 1 diabetes, levels of fasting C‐peptide, peak value of C‐peptide during a 75‐g oral glucose tolerance test, and area under C‐peptide release curve during an oral glucose tolerance test, showed no significant differences between *A33‐DR3*‐positive carriers and *A33‐DR3*‐negative carriers (Table S11). For the *A33‐DR9*‐positive and *A33‐DR9*‐negative subgroups, there were also no significant differences in any clinical characteristics.

Immunological Features in Type 1 Diabetic Patients Consistent with High‐risk *A33‐DR3* and *A33‐DR9* Haplotypes {#jdi12462-sec-0015}
---------------------------------------------------------------------------------------------------------------

Haplotype *A33‐DR3* was associated with the imbalance of T lymphocyte subpopulations at the onset of type 1 diabetes (Figure [1](#jdi12462-fig-0001){ref-type="fig"}), and an example of the gating strategy and fluorescence activated cell sorter plots is shown in Figure [2](#jdi12462-fig-0002){ref-type="fig"}. Compared with *A33‐DR3*‐negative carriers, *A33‐DR3*‐positive carriers had a significantly lower percentage of CD3^+^CD4^+^ T cells (42.5 ± 7.72 vs 37.0 ± 8.35%, *P* = 0.023), higher percentage of CD3^+^CD8^+^ T cells (27.4 ± 7.09 vs 32.8 ± 5.98%, *P* = 0.005) and lower level of ratio of CD4/CD8 (1.71 ± 0.75 vs 1.16 ± 0.35, *P* = 0.003). In addition, *A33‐DR3*‐positive carriers had a significantly higher percentage of T‐cell receptor (TCR) α/β(TCR1^+^) T cells than the *A33‐DR3*‐negative carriers (73.6 ± 6.25 vs 70.0 ± 7.00%, *P* = 0.031). However, the percentages of CD45RA^+^CD62L^+^ lymphocytes, neutrophils, natural killer (CD16^+^CD56^+^) cells and the IgG‐producing B (CD19^+^) cells were not significantly different between the two subgroups. None of the serum protein levels measured, such as glutamic acid decarboxylase antibodies, hs‐CRP, IgG and IFN‐γ, appeared to be associated with *A33‐DR3*. No significant differences were found in any immunological features between *A33‐DR9*‐positive carriers and *A33‐DR9*‐negative patients, except for CD3^+^CD4^+^ T cells and CD4/CD8, respectively (34.8 ± 13.71 vs 44.3 ± 8.48%, *P* = 0.022; 1.07 ± 0.46 vs 1.76 ± 0.72, *P* = 0.042), To evaluate whether the observed associations of an altered phenotype in lymphocytes is associated with the A33‐DR3 haplotype or with type 1 diabetes, we tested the T lymphocyte subpopulations in 10 healthy participants to evaluate controls by flow cytometry. The data is organized as Figures [1](#jdi12462-fig-0001){ref-type="fig"}, S1 and S2. Although there were no significant differences in the percentages of CD3^+^CD4^+^ T cells and CD3^+^CD8^+^ T cells, A33‐DR3‐positive carriers had the lowest ratio of CD4/CD8. Compared with healthy controls, *A33‐DR3*‐positive carriers and *A33‐DR3*‐negative carriers had a significantly higher percentage of TCRα/β T cells, respectively (58.7 ± 9.12 vs 73.6 ± 6.25%, *P* = 2.6 × 10^−6^; 58.7 ± 9.12 vs 69.7 ± 7.00%, *P* = 9.5 × 10^−5^). Compared with *A33*‐negative carriers, *A33*‐positive carriers also had a significantly lower level of ratio of CD4/CD8 (1.75 ± 0.68 vs 1.16 ± 0.35, *P* = 2.3 × 10^−6^). No significant differences were found in CD4/CD8 ratio between DR3‐positive carriers and DR3‐negative patients.

![Association of *A33‐DR3* haplotype and T lymphocyte subpopulations in type 1 diabetes patients (\**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001). (a) CD3^+^ CD4^+^ T cells. (b) CD3^+^ CD8^+^ T cells. (c) Ratio of CD4/CD8. (d) CD45RA ^+^ CD62L^+^ lymphocytes. (e) TCRα/β(TCR1^+^) T cells. (f) Natural killer (NK;CD16^+^ CD56^+^) cells. Vertical lines indicate one standard deviation above and below the mean. There were 41, 126 and 10 participants in the A33^+^ DR3^+^, DR3^--^A33^--^ subgroups and healthy control (NC) group, respectively. [anova]{.smallcaps} after adjustments for age of onset and duration of diabetes.](JDI-7-514-g001){#jdi12462-fig-0001}

![Flow cytometry results in a sample patient. Gating of lymphocytes were adjusted according to forward scatter (FSC) and side scatter (SSC). (a) Six color: anti‐CD45‐PerCP‐Cy5.5, anti‐CD3‐FITC, anti‐CD4‐PE‐Cy7, anti‐CD8‐APC‐H7, anti‐CD19‐APC and anti‐CD16^+^56‐PE. Having gated on (a1) CD45^+^ cells, we counted (a2) CD3^+^, (a3) CD3^+^ CD4^+^, (a3) CD3^+^ CD8^+^, (a4) NK (CD16^+^ CD56^+^) and (a5) B (CD19^+^) cells. (b) Three color: anti‐CD45‐PerCP‐Cy5.5, anti‐CD45RA‐FITC and anti‐C62L‐PE. Having gated on (b1) CD45^+^ cells, we counted (b2) CD45RA ^+^ CD62L^+^ lymphocytes. (c) Three color: anti‐CD45‐PerCP‐Cy5.5, anti‐TCR1‐FITC (TCRαβ) and anti‐TCR2‐PE (TCRγδ). Having gated on (c1) CD45^+^ cells, we counted (c2) TCRα/β T cells.](JDI-7-514-g002){#jdi12462-fig-0002}

Discussion {#jdi12462-sec-0016}
==========

Several studies have suggested that extended or ancestral major histocompatibility complex haplotypes provide an even greater risk to develop autoimmunity compared with individual alleles of any single gene[9](#jdi12462-bib-0009){ref-type="ref"}, [10](#jdi12462-bib-0010){ref-type="ref"}. Thus, we mainly focused on the susceptibility of haplotypes for *HLA* class I/II in the present study.

In our study, we defined two sets of *HLA*‐*A33* ^*+*^ haplotypes that provide maximum risk of type 1 diabetes development in Chinese: the *A33‐DR3* haplotype and *A33‐DR9* haplotype. According to published literature, *A\*33:03‐B\*58:01‐C\*03:02‐DRB1\*03:01* is reported as a relatively common haplotype in the Han Chinese population[11](#jdi12462-bib-0011){ref-type="ref"}, [12](#jdi12462-bib-0012){ref-type="ref"}, [13](#jdi12462-bib-0013){ref-type="ref"}. As there were no linkage disequilibrium between the haplotype *A33* and *DR3*, the positive association of *A33‐DR3* with type 1 diabetes might be the accumulation of specific *HLA* class I and class II. In the North Indian population, *A2‐B8‐DR3* contributed the maximum risk (relative risk = 48.7) for type 1 diabetes, followed by *A2‐B50‐DR3* (relative risk = 9.4) and *A33‐B58‐DR3* (relative risk = 6.6)[14](#jdi12462-bib-0014){ref-type="ref"}. It is interesting to note that the *A33‐B58‐DR3* haplotype also shows positive disease‐association in Mongoloid racial groups[15](#jdi12462-bib-0015){ref-type="ref"}. These results support the hypothesis that certain combined haplotypes have subsequently expanded in frequency across populations in different geographical location. The fact that neither A\*33:03 nor B\*58:01 appears type 1 diabetes predisposing when seen in Caucasians (e.g., in the T1DGC data) suggests that the effect seen in Asians might not be due to the alleles themselves, but to something else on the haplotype.

The mechanism of the accumulation of specific *HLA* class I and class II (*DR* and *DQ*) alleles causing higher risk in type 1 diabetes remains unclear. The combination of specific *HLA*‐*A*,*‐DR* and ‐*DQ* alleles might have synergic and complementary effects on various steps of the immune response. Furthermore, the odds ratio of *A33‐DR3* and *A33‐DR9* was just 5.09 and 13.0, respectively, in new‐onset type 1 diabetes, so there remains the possibility that there is synergy between these two haplotypes and non‐*HLA* genes[16](#jdi12462-bib-0016){ref-type="ref"} or environmental factors, such as viral infection[17](#jdi12462-bib-0017){ref-type="ref"}, in promoting insulitis in type 1 diabetes. According to the study by Chang *et al*.[18](#jdi12462-bib-0018){ref-type="ref"}, multivariate analysis showed that HLA‐A33 was the gene most significantly susceptible to enterovirus 71. There have been several studies to investigate enterovirus\'s potential role as an environmental factor in predisposing to type 1 diabetes, though these results remain controversial[19](#jdi12462-bib-0019){ref-type="ref"}, [20](#jdi12462-bib-0020){ref-type="ref"}, [21](#jdi12462-bib-0021){ref-type="ref"}, [22](#jdi12462-bib-0022){ref-type="ref"}, [23](#jdi12462-bib-0023){ref-type="ref"}.

The significant association of the haplotype *A33‐DR3* with the abnormality in the ratio of helper to cytotoxic T cells is consistent with our hypothesis. Given that a previous study found that the persistence of a reduced CD4/CD8 lymphocyte ratio (less than 1.5) might reflect the ongoing process leading to β‐cell destruction[24](#jdi12462-bib-0024){ref-type="ref"}, longitudinal observation of β‐cell function is necessary to better elucidate the genetic factors that regulate the natural course of β‐cell destruction in type 1 diabetes. Furthermore, as the decreased CD4/CD8 ratio \<1 is one of the features leading to the introduction of an immune‐risk phenotype (i.e., immunosenescence), the present results suggest that 'immunosenescence,' or premature aging of the immune system, could contribute to the development of autoimmune diseases[25](#jdi12462-bib-0025){ref-type="ref"}. One surprising finding is that the CD4/CD8 ratio was significantly lower in A33(+) carriers than A33(−), but was not significantly changed between DR3(+) and DR3(−). This point is very interesting compared with the absence of the association of the A33 haplotype alone with type 1 diabetes, and might indicate important roles of *HLA* class I in immune modulation in the disease.

TCRα/β chains are heterodimeric membrane proteins expressed on the surface of T cells, and they contribute to direct recognition of antigen peptide presented on the major histocompatibility complex in the target cells[26](#jdi12462-bib-0026){ref-type="ref"}, [27](#jdi12462-bib-0027){ref-type="ref"}, so it is reasonable to observe higher TCRα/β T cells in the *A33‐DR3*‐positive carriers.

In contrast, none of the serum protein and cells in innate immunity appeared to be associated with the haplotype *A33‐DR3*. According to the study by Diana *et al*.[5](#jdi12462-bib-0005){ref-type="ref"}, IgG‐producing B cells (CD19^+^), neutrophils and IFN‐γ production in circulation are required for the initiation of the diabetogenic T cell response and type 1 diabetes development. This suggests that repertoire selection in type 1 diabetes could preferentially favor self‐reactive T cells, because the HLA‐A molecule presents the insulin self‐peptide, favoring both a smaller number of surviving T cells and a higher percentage of self‐reactivity[28](#jdi12462-bib-0028){ref-type="ref"}.

In regard to clinical parameters, male sex, a younger age at onset, diabetic ketoacidosis history at onset, a father or sibling with type 1 diabetes and longer duration are independent risk factors for early complete β‐cell destruction in type 1 diabetes[29](#jdi12462-bib-0029){ref-type="ref"}, [30](#jdi12462-bib-0030){ref-type="ref"}. However, in the present study, clinical features showed no significant differences between the patients with or without the above‐mentioned *HLA* haplotypes. This might have been due to a narrow range of the age of onset and short duration (less than 6 months) in the present study population as a result of including young patients with new‐onset type 1 diabetes, who are mostly in the primary stage of disease. In a Japanese longitudinal study (median 10 years), patients who possessed *HLA*‐*A24*,*HLA‐DQA1\*03* and *HLA*‐*DR9* together showed complete loss of β‐cell function much earlier than those who did not have this three‐allele combination[31](#jdi12462-bib-0031){ref-type="ref"}.

Although the present study showed the temporal profile of a disruption of particular immunological cell networks in type 1 diabetes and detected two *HLA* haplotypes that enhanced the risk of type 1 diabetes, its retrospective design is a limitation with respect to delineating the association between genetic factors and longitudinal changes of residual β‐cell function. In addition, as the frequency of *A33‐DR3* and *A33‐DR9* was just 19.3% and 6.1%, respectively, in the new‐onset type 1 diabetes group, the low frequencies of these haplotypes make it possible that the study was insufficiently powered to find an association with clinical phenotypes. Long‐term prospective studies with larger samples on residual β‐cell function using the stimulated C‐peptide response would be preferable.

This is the first study to report that haplotype *A33‐DR3* and *A33‐DR9* were found to predispose patients, and to enhance the risk of type 1 diabetes. Furthermore, *A33‐DR3* and *A33‐DR9* were shown to be associated with a reduction in the helper‐to‐cytotoxic cell ratio (CD4/CD8 ratio) in the initiation of type 1 diabetes. In particular, a preferential increase of TCRα/βT cell subpopulations was found in the *A33‐DR3*‐positive carriers compared with *A33‐DR3*‐negative carriers. In contrast, no relationship was observed between these two haplotypes and the clinical features at onset or the innate immunology. These findings show that typing for *HLA* class I and its immunogenetic effects are important for more accurate *HLA* class II haplotype risk prediction and further revelatory etiology research in type 1 diabetic patients.
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**Figure S1** ¦ Association of *A33‐DR3* haplotype and T lymphocyte subpopulations (%) in type 1 diabetes patients.
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**Figure S2** ¦ Association of *A33‐DR3* haplotype and T lymphocyte subpopulations (\*10^9^/L) in type 1 diabetes patients.
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